What Does Paroxetine Deplete? 3 Nutrients Affected

Paroxetine is a serotonin transporter inhibitor prescribed to approximately 10 million Americans annually under the brand names Paxil, Paxil CR, and Brisdelle for major depressive disorder, generalized anxiety disorder, social anxiety disorder, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and premenstrual dysphoric disorder. According to ChEMBL mechanism-of-action data, paroxetine also demonstrates significant anticholinergic activity and weak norepinephrine reuptake inhibition, distinguishing it from more selective SSRIs like escitalopram. With oral bioavailability of 45%, peak plasma concentration at 4.3 hours, 95% protein binding, and an elimination half-life of 21 hours, paroxetine achieves extensive tissue distribution throughout the central nervous system. The short half-life combined with the absence of active metabolites makes paroxetine the most difficult SSRI to discontinue, producing withdrawal symptoms so severe that the phenomenon has its own clinical designation: SSRI discontinuation syndrome. This pharmacokinetic profile also means the drug's effects on nutrient metabolism fluctuate more sharply between doses than longer-acting agents like fluoxetine.

The Comparative Toxicogenomics Database catalogs 51 gene interactions for paroxetine, with 1,905 total disease associations and 144 curated disease links. Among SSRIs, paroxetine possesses the strongest anticholinergic properties, which contribute to its distinctive depletion profile beyond standard serotonergic effects. The anticholinergic burden affects gastrointestinal motility and nutrient absorption, while the potent serotonin reuptake inhibition drives folate demand through the BH4-dependent serotonin synthesis pathway. SIADH-induced hyponatremia occurs because excessive serotonin signaling in hypothalamic neurons stimulates vasopressin release, and paroxetine's high SERT binding affinity produces more pronounced vasopressin stimulation than other SSRIs. The drug's norepinephrine reuptake activity adds an additional dimension of catecholamine-related nutrient demand, further taxing the methylation cycle that depends on adequate folate and B12 status. Weight gain is more common with paroxetine than other SSRIs, compounding the metabolic burden and potentially affecting fat-soluble vitamin status.

PharmGKB pharmacogenomic annotations for paroxetine include documentation of CYP2D6 polymorphisms that dramatically alter drug metabolism and, consequently, the severity of nutrient depletion effects. Poor CYP2D6 metabolizers experience drug concentrations up to 7-fold higher than extensive metabolizers at identical doses, intensifying every downstream nutrient interaction proportionally. Across the 254 randomized controlled trials encompassing 120,623 patients cataloged in Kelda's knowledge graph, paroxetine consistently demonstrates the highest incidence of SIADH among SSRIs, with the FAERS database documenting hyponatremia, thrombocytopenia, and dizziness among the most reported serious outcomes. The 1,669 PubMed articles indexed for paroxetine provide an extensive clinical evidence base confirming that folate status modifies treatment response, melatonin disruption drives the insomnia commonly reported in the first weeks of therapy, and sodium monitoring within the initial month of treatment prevents the most dangerous acute depletion. CYP2D6 genotype-guided dosing can identify patients at highest risk for severe nutrient depletion before prescribing.